BioAegis Therapeutics, Inc.

BioAegis Therapeutics, Inc.

生物技术研究

North Brunswick,New Jersey 2,112 位关注者

Commercializing a key component of the immune system, #Gelsolin, for infectious, inflammatory and degenerative diseases.

关于我们

Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.

网站
https://www.bioaegistherapeutics.com
所属行业
生物技术研究
规模
11-50 人
总部
North Brunswick,New Jersey
类型
私人持股
创立
2011

地点

  • 675 US Route 1

    US,New Jersey,North Brunswick,08902

    获取路线

BioAegis Therapeutics, Inc.员工

动态

相似主页

查看职位

融资

BioAegis Therapeutics, Inc. 共 6 轮

上一轮

未知

US$22,000,000.00

Crunchbase 上查看更多信息